Leo Gordon, MD
Professor of Medicine (Hematology and Oncology)
The overarching goal of my involvement in translational research is to improve the outcome of patients with lymphoma. With scientists in the US and abroad, we are currently investigating novel signaling pathways in lymphoma, using cell lines and animal model systems. More specifically, our research focuses on 1) The characterization of cholesterol efflux pumps as a target in lymphoma, in collaboration with Dr Colby Shad Thaxton from the Department of Urology and the Northwestern University Center of Cancer Nanotechnology excellence. We have used bio inspired lipoprotein gold nanoparticles to induce alteration in membrane choleserol flux, leading to upregulation of cholesterol synthesis genes and down-regulation of glutathione peroxidase 4 (GPX4), a process that leads to ferroptotic cell death in lymphoma and other cholesterol addicted malignancies; 2) the study of hypoxia inducible factor (HIF) in lymphoma, in collaboration with Dr. Paul Schumacker; 3) the study of CpG oligonucleotides delivered by hollow gold nanoparticles in collaboration with Dr Adam Lin, a post doctoral fellow in the Robert H. Lurie Comprehensive Cancer Center; 4) the study of lactone diterpenoids in lymphoma biology. Clinical research interests include 5) the study of CAR-t cells in lymphoma clinical trials; 6) novel biologic agents in Hodgkins and non-Hodgkins lymphoma; 7) stemcell transplantation in lymphoma. Clinical research studies are carried out through the Northwestern University Lymphoma Program and through national co-operative groups such as the Eastern Cooperative Oncology Group (ECOG), SPORE programs in lymphoma and through pharma.
Northwestern University Feinberg School Of Medicine: Arkes Pavilion, 676 N St Clair St Ste 850, Chicago, IL 60611, USA